TYRA BIOSCIENCES INC (TYRA) Stock Overview
USA - NASDAQ:TYRA - US90240B1061 - Common Stock
TYRA Key Statistics, Chart & Performance
The current stock price of TYRA is 12.52 USD. In the past month the price increased by 17.01%. In the past year, price decreased by -41.05%.
TYRA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.62 | 385.71B | ||
| AMGN | AMGEN INC | 12.67 | 148.80B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 142.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.29 | 101.15B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.07B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.27 | 59.35B | ||
| ARGX | ARGENX SE - ADR | 81.59 | 46.29B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.67 | 38.56B | ||
| INSM | INSMED INC | N/A | 30.85B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.26B | ||
| NTRA | NATERA INC | N/A | 23.13B | ||
| BIIB | BIOGEN INC | 9.05 | 21.24B |
Related stock screener links
About TYRA
Company Profile
Tyra Biosciences, Inc. is a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer. The company is headquartered in Carlsbad, California and currently employs 60 full-time employees. The company went IPO on 2021-09-15. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. The company has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. The company is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.
Company Info
TYRA BIOSCIENCES INC
2656 State Street
Carlsbad CALIFORNIA US
CEO: Todd Harris
Employees: 60
Phone: 16197284760
TYRA BIOSCIENCES INC / TYRA FAQ
What is the stock price of TYRA BIOSCIENCES INC today?
The current stock price of TYRA is 12.52 USD. The price increased by 0.4% in the last trading session.
What is the ticker symbol for TYRA BIOSCIENCES INC stock?
The exchange symbol of TYRA BIOSCIENCES INC is TYRA and it is listed on the Nasdaq exchange.
On which exchange is TYRA stock listed?
TYRA stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TYRA BIOSCIENCES INC stock?
14 analysts have analysed TYRA and the average price target is 31.62 USD. This implies a price increase of 152.56% is expected in the next year compared to the current price of 12.52. Check the TYRA BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TYRA BIOSCIENCES INC worth?
TYRA BIOSCIENCES INC (TYRA) has a market capitalization of 667.32M USD. This makes TYRA a Small Cap stock.
How many employees does TYRA BIOSCIENCES INC have?
TYRA BIOSCIENCES INC (TYRA) currently has 60 employees.
What are the support and resistance levels for TYRA BIOSCIENCES INC (TYRA) stock?
TYRA BIOSCIENCES INC (TYRA) has a support level at 12.51 and a resistance level at 12.61. Check the full technical report for a detailed analysis of TYRA support and resistance levels.
Should I buy TYRA BIOSCIENCES INC (TYRA) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TYRA, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TYRA, evaluating the profitability, health, valuation and growth aspects
- TYRA BIOSCIENCES INC (TYRA) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TYRA BIOSCIENCES INC (TYRA) Sales and EPS estimates to see what analysts future expectations are.
- TYRA BIOSCIENCES INC (TYRA) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TYRA BIOSCIENCES INC (TYRA) Insider and Institutional Ownership to learn about the owners and their transactions.
- TYRA BIOSCIENCES INC (TYRA) Stock Chart to make your own analysis
- TYRA BIOSCIENCES INC (TYRA) Latest news and press-releases to stay up to date.
Does TYRA BIOSCIENCES INC (TYRA) stock pay dividends?
TYRA does not pay a dividend.
When does TYRA BIOSCIENCES INC (TYRA) report earnings?
TYRA BIOSCIENCES INC (TYRA) will report earnings on 2025-11-05, after the market close.
What is the Price/Earnings (PE) ratio of TYRA BIOSCIENCES INC (TYRA)?
TYRA BIOSCIENCES INC (TYRA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.78).
What is the Short Interest ratio of TYRA BIOSCIENCES INC (TYRA) stock?
The outstanding short interest for TYRA BIOSCIENCES INC (TYRA) is 11.36% of its float. Check the ownership tab for more information on the TYRA short interest.
TYRA Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to TYRA. When comparing the yearly performance of all stocks, TYRA is a bad performer in the overall market: 83.94% of all stocks are doing better.
TYRA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TYRA. No worries on liquidiy or solvency for TYRA as it has an excellent financial health rating, but there are worries on the profitability.
TYRA Financial Highlights
Over the last trailing twelve months TYRA reported a non-GAAP Earnings per Share(EPS) of -1.78. The EPS decreased by -5.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.92% | ||
| ROE | -35.03% | ||
| Debt/Equity | 0 |
TYRA Forecast & Estimates
14 analysts have analysed TYRA and the average price target is 31.62 USD. This implies a price increase of 152.56% is expected in the next year compared to the current price of 12.52.